Product DemonstrationsLife Sciences

TransIT BrCa Transfection Reagent

21 Oct 2014
TransIT BrCa Transfection Reagent

Watch this video to learn more about the TransIT-BrCa Transfection Reagent, the first dedicated breast cancer cell line specific reagent. While it delivers efficiently to many breast cancer cell types, it also maintains low cellular toxicity resulting in reduced experimental biases.

About the company

Mirus Bio LLC logo

Mirus Bio LLC

Mirus Bio LLC is a life science company focused on discovering, developing and commercializing innovative nucleic acid based technologies and products.

Mirus R&D uniquely integrates nucleic acid delivery and chemistry, a core competency which is unmatched in the industry. This serves as the foundation for its novel research reagents.

4.8/5.0
|11 Reviews

TransIT®-BrCa Transfection Reagent

Mirus Bio LLC

Superior DNA transfection of breast cancer cell typesTransIT-BrCa Transfection Reagent is the first dedicated breast cancer cell line specific reagent available to researchers today. While it delivers efficiently to many breast cancer cell types, it also maintains low cellular toxicity resulting in reduced experimental biases. TransIT®-BrCa Transfection Reagent is specifically optimized to provide exceptional transfection efficiency of plasmid DNA in breast cancer and related cell types including: MCF-7, MDA-MB-231 and T47D cells.TransIT®-BrCa Transfection Reagent Features:•Broad Spectrum DNA Delivery - Achieve high expression levels in breast cancer cell types including: MCF-7, MDA-MB-231, MDA-MB-453, MDA-MB-468, and T47D.•Formulated for Low Cellular Toxicity - Maintain cell density and reduce experimental biases due to toxicity.•Superior Transfection Efficiency - TransIT®-BrCa outperforms Lipofectamine® 2000, in multiple breast cancer cell lines.

(0)

Other videos from Mirus Bio LLC

Links